Date
22 March 2023
‘I skip meals to make my insulin last’: the cost of diabetes in the global south
Writing for the Guardian, Weronika Strzyżyńska looks at the global disparities in the cost of insulin, speaking to Claudia Martínez, the Foundation's Research Programme Manager.
Direct links
Despite recent commitments by the three companies that control the majority of the market to cutting the cost of insulin in the US, those living with diabetes in low- and middle-income countries (LMICs) are unlikely to benefit. The article picks up on the fact that the three main manufacturers produce 83% of the insulin sold in LMICs, as stated in the Foundation's 2022 report on access to insulin.
Read the article on the Guardian website.